Metabolic tracking technology developer Ultrahuman announced today that it appointed Bhuvan Srinivasan as its first chief chief business officer.
The appointment of Srinivasan to the new role follows Bangalore, India-based Ultrahuman’s $17.5 million Series B financing round completed in August.
Ultrahuman develops the Ultrahuman Cyborg, a continuous metabolism tracker designed to help people with diabetes track blood glucose in real-time and optimize their diet and exercise. The company says its platform goes beyond traditional markers like body mass index, weight and point-in-time blood tests, utilizing biomarkers to tell users how their body reacts to a certain type of food, how to fuel efficiently for exercise and how to eat for better sleep.
Bhuvan’s experience prior to joining Ultrahuman includes more than 14 years in consultancy and private equity. He most recently served as a director in KKR’s India team, leading investments in pharma, hospitals, waste management, tech and education, according to a news release.
“We are navigating our scale-up journey and having people like Bhuvan will certainly bolster our efforts,” Ultrahuman founder & CEO Mohit Kumar said in the release. His appointment is part of the next phase of growth and his experience in building businesses will provide the perspective and guidance Ultrahuman requires as we charter the course.”
He also held positions with Bain Capital and Bain & Company. He began his career as a research scientist working on continuous glucose monitoring with Medtronic’s diabetes arm in Los Angeles.
“Life has come full circle for me in joining Ultrahuman. I began my career as a research scientist for glucose sensors for diabetes. Since then, I have benefitted from working closely with a range of businesses and people, skills that I will be able to utilize in driving the future trajectory of Ultrahuman as it scales globally,” added Srinivasan. “Research over the last 15 years has shown that good glucose control is important for preventing other diseases as well, including cardiovascular disease, Alzheimer’s and even cancer. I have been an avid supporter of the business over the years and am thrilled to be joining this amazing group of people who are focussed on making a huge impact.”